ATE175211T1 - Neues, biologisch aktives, vom frosch stammendes peptid (frosch-cnp) - Google Patents

Neues, biologisch aktives, vom frosch stammendes peptid (frosch-cnp)

Info

Publication number
ATE175211T1
ATE175211T1 AT91115079T AT91115079T ATE175211T1 AT E175211 T1 ATE175211 T1 AT E175211T1 AT 91115079 T AT91115079 T AT 91115079T AT 91115079 T AT91115079 T AT 91115079T AT E175211 T1 ATE175211 T1 AT E175211T1
Authority
AT
Austria
Prior art keywords
frog
cnp
biologically active
derived peptide
new biologically
Prior art date
Application number
AT91115079T
Other languages
English (en)
Inventor
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Original Assignee
Suntory Ltd
Hisayuki Matsuo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd, Hisayuki Matsuo filed Critical Suntory Ltd
Application granted granted Critical
Publication of ATE175211T1 publication Critical patent/ATE175211T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
AT91115079T 1990-09-07 1991-09-06 Neues, biologisch aktives, vom frosch stammendes peptid (frosch-cnp) ATE175211T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2238294A JP2977159B2 (ja) 1990-09-07 1990-09-07 カエル由来新規生理活性ペプチド(カエルcnp)

Publications (1)

Publication Number Publication Date
ATE175211T1 true ATE175211T1 (de) 1999-01-15

Family

ID=17028056

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91115079T ATE175211T1 (de) 1990-09-07 1991-09-06 Neues, biologisch aktives, vom frosch stammendes peptid (frosch-cnp)

Country Status (8)

Country Link
US (1) US5336759A (de)
EP (1) EP0475290B1 (de)
JP (1) JP2977159B2 (de)
AT (1) ATE175211T1 (de)
DE (1) DE69130695T2 (de)
DK (1) DK0475290T3 (de)
ES (1) ES2127189T3 (de)
GR (1) GR3029632T3 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
ES2465141T3 (es) 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
KR20070007842A (ko) 2004-03-31 2007-01-16 카즈와 나카오 신장증가용 조성물
PL1759001T3 (pl) 2004-04-21 2011-09-30 Alexion Pharma Inc Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
US20100204107A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of urodilatin as a therapeutic agent
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ, インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ, インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
JP6993961B2 (ja) 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼの製造
EP3355904A4 (de) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifizierung wirksamer dosierungsschemata für gewebeunspezifische alkalische phosphatase-enzymersatztherapie von hypophosphatasie
EP3368062A4 (de) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von craniosynostose bei einem patienten
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
KR20180125979A (ko) 2016-04-01 2018-11-26 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ, インコーポレイテッド 気管気管支軟化症の治療方法
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12611447B2 (en) 2020-09-04 2026-04-28 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
AU2022218782B2 (en) 2021-02-12 2026-06-25 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544929B2 (ja) * 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
ES2127189T3 (es) 1999-04-16
US5336759A (en) 1994-08-09
DK0475290T3 (da) 1999-08-30
EP0475290B1 (de) 1998-12-30
EP0475290A1 (de) 1992-03-18
DE69130695T2 (de) 1999-06-10
JPH04120095A (ja) 1992-04-21
GR3029632T3 (en) 1999-06-30
DE69130695D1 (de) 1999-02-11
JP2977159B2 (ja) 1999-11-10

Similar Documents

Publication Publication Date Title
DE69130695D1 (de) Neues, biologisch aktives, vom Frosch stammendes Peptid (Frosch-CNP)
DE69130696D1 (de) Ein neues, biologisch aktives vom Huhn stammendes Peptid (Huhn-CNP)
ATE145914T1 (de) Anticonvulsive fructopyranose zyklische sulfate und sulfite
BR1100989A (pt) Composto e composição de matéria
IT8921742A0 (it) Procedimento per la purificazione delle acque reflue prodotte dagli impianti di produzione dell'urea.
DK0696937T3 (da) Fremgangsmåde til behandling af spontant forbrændelige katalysatorer
FI885504A0 (fi) Vaskulaera antikoagulerande proteiner, dessa koderande dna, deras framstaellningsfoerfarande och deras anvaendning.
ATE152734T1 (de) Bpc-peptide, deren herstellung und verwendung
PT641215E (pt) Analogos de trombomodulina resistentes a proteases
DE69010442D1 (de) Reinigung von 1,1-Dichlor-1-fluorethan.
DE3787112D1 (de) Menschliche Pankreaselastase I.
DE69534470D1 (de) Lgmd- gen kodierend für einer calcium abhängigen protease
DE69116803D1 (de) Peroxidase-Gen von mikrobischem Ursprung
DE59602774D1 (de) Verfahren zur Herstellung von 3.3.5-Trimethylcyclohexanon
ATE209683T1 (de) Planze resistent gegen mindestens zwei viren und dessen preparation
DE59904211D1 (de) Verfahren zur Reinigung und Isolierung von 2,3,5-Trimethyl-p-benzochinon
ATE92077T1 (de) Enzymhemmer und methode zu dessen herstellung.
IT8423089A0 (it) Solubilizzazione di ossigeno mediante adsorbimento dell'ossigeno nei fanghi biologici degli impianti di depurazione a fanghi attivi.
FI873353A7 (fi) Jätevesien biologinen käsittelytapa kaskadimaisesti toimivan uppobiosuodatuslaitoksen avulla.
IT8941638A0 (it) Procedimento ed impianto per il recupero di bitartrato di potassio dalle acque reflue di rigenerazione di impianti di deionizzazione del mosto d'uva.
ATE49964T1 (de) Benzodioxepane, verfahren zur herstellung und verwendung als heilmittel.
IT9047825A0 (it) Impianto prefabbricato per il procedimento di trattamento di depurazione di liquami fognari cittadini, o scarichi industriali.
SE8403252L (sv) Forfarande vid forbrenning, jemte brensle
DE3765250D1 (de) Verwendung von 24,25-dihydroxycholecalciferol zur behandlung von harnsteinen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee